Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10046482HBVENSG00000010671.18protein_codingBTKYesNo695Q06187
Q5JY90
TVIS10057601HBVENSG00000010671.18protein_codingBTKYesNo695Q06187
Q5JY90
TVIS30021024HIVENSG00000010671.18protein_codingBTKYesNo695Q06187
Q5JY90
TCGA Plot Options
Drug Information
GeneBTK
DrugBank IDDB17472
Drug NamePirtobrutinib
Target IDBE0001284
UniProt IDQ06187
Regulation Typeinhibitor
PubMed IDs35747462; 33676628
CitationsJensen JL, Mato AR, Pena C, Roeker LE, Coombs CC: The potential of pirtobrutinib in multiple B-cell malignancies. Ther Adv Hematol. 2022 Jun 16;13:20406207221101697. doi: 10.1177/20406207221101697. eCollection 2022.@@Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M: Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 Mar 6;397(10277):892-901. doi: 10.1016/S0140-6736(21)00224-5.
GroupsApproved; Investigational
Direct Classification
SMILESCOC1=C(C=C(F)C=C1)C(=O)NCC1=CC=C(C=C1)C1=NN([C@@H](C)C(F)(F)F)C(N)=C1C(N)=O
Pathways
PharmGKB
ChEMBLCHEMBL4650485